(ZLAB) – FDA
-
Zai Lab (ZLAB) Obtains Breakthrough Therapy Designation for Efgartigimod Alfa Injection (Subcutaneous Injection) in Patients with Chronic Inflammatory Demyelinating Polyneuropathy in China
-
Zai Lab Limited (ZLAB) and argenx Announce Approval of VYVGART for Generalized Myasthenia Gravis in China
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Back to ZLAB Stock Lookup